Skip to content

Thieno[2,3-d]pyrimidin-4(3H)-one derivatives: Discovery of a potent compound and its combination with photodynamic therapy against pancreatic cancer.

Nov 2026 · European journal of medicinal chemistry · Vol 322, pp. 119494 · 0 citations · 32 references
Medicine

Abstract

To develop novel small-molecule candidates for pancreatic cancer therapy, a series of thieno[2,3-d]pyrimidin-4(3H)-one derivatives were designed and synthesized. Following cell-based evaluation, compound A8 displayed potent in vitro antiproliferative activity against PANC-1 cells with an IC50 of 4.89 ± 0.25 nM. Systematic pharmacodynamic assessments confirmed the potent antitumor efficacy of A8 in both the in vitro cellular models and in vivo xenograft models. Preliminary mechanistic studies showed that target identification from kinase profiling implicated PI3Kα as a potential molecular target. Molecular docking and molecular dynamics simulations suggested that A8 might have favorable binding affinity for PI3Kα. Moreover, combined treatment with A8 and verteporfin-based photodynamic therapy increased intracellular ROS and exerted synergistic proliferation inhibition against PANC-1 cancer cells. This study identifies A8, a potent thieno[2,3-d]pyrimidin-4(3H)-one small molecule that suppresses PANC-1 proliferation, and proposes a feasible and promising combination strategy pairing A8 with photodynamic therapy for pancreatic cancer treatment. These findings highlight compound A8 as a promising candidate for the development of anti-pancreatic cancer therapeutics.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.